PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Constipation (Bisacodyl - Constipation)

Records returned : 24 (on 04 Nov 2025 at 06:03:58). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
01.06.02
Bisacodyl
Constipation
Green
Formulations :
  • Suppositories
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
NOTE - 7.5mg suppositories are non-formulary. Only the licensed 5mg and 10mg suppositories should be prescribed
01.06.02
Constipation
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
U
Important
7.5mg suppositories are unlicensed and not approved for use in Surrey Heartlands.
01.06.02
12.01.03
Docusate sodium
Constipation
Green
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.02
12.01.03
Constipation
Green
Formulations :
  • Enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.04
01.06.05
Macrogol compound
Constipation
Green
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Prescribe as macrogol compound oral powder sachets. MHRA/CHM advice: Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect.
01.06.04
Magnesium hydroxide
Constipation
Green
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.07
Prucalopride
Constipation
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Only after a trial of at least 2 other classes of laxative at the highest recommended, tolerated doses. Consider stopping after 4 weeks if not effective.
01.06.02
01.06.05
Sodium picosulfate
Constipation
Green
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.04.01
01.06.01
Sterculia
Constipation
Green
Formulations :
  • Sachets (granules)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.02
Glycerol
Constipation
Green
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.01
Ispaghula husk
Constipation
Green
Formulations :
  • Sachets (granules)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.04
Lactulose
Constipation
Green
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.06
Naldemedine
Constipation
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
R
NICE
Important
Opioid-induced constipation. Only after other laxatives have been unsuccessful.
01.06.04
Phosphates (Rectal)
Constipation
Green
Formulations :
  • Enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Contraindicated in patients with CKD, dehydration and heart failure (among others).
01.06.02
Senna
Constipation
Green
Formulations :
  • Liquid
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.04
Sodium citrate (Rectal)
Constipation
Green
Formulations :
  • Enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.03
Arachis oil
Constipation
Green
Formulations :
  • Enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Allergy warning - contains peanut oil
01.06.06
Naloxegol
Constipation
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Opioid-induced constipation. Only after other laxatives have been unsuccessful.
01.06.02
Co-danthramer
Constipation
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Only for use in end-of-life patients
01.06.02
Co-danthrusate
Constipation
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Only for use in end-of-life patients
01.06.04
01.06.05
Macrogol compound
Constipation
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Un
Important
Moviprep / Plenvu - ADULTS only. Off-label use. MHRA/CHM advice: Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect.
01.06.02
01.06.05
Sodium picosulfate
Constipation
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
PICOLAX sachets - off-label use. ADULTS only at SASH. Adults and children at RSFT.
01.06.02
01.06.05
Constipation
Red
Formulations :
  • Sachets (powder)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
CITRAFLEET - ADULTS only. Off-label use
01.06.06
Methylnaltrexone bromide
Constipation
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
For opioid-induced constipation in terminally ill patients when response to other laxatives is inadequate
RSCH Palliative Care Team only
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More